{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:10:03Z","timestamp":1794867003912,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Orforglipron, a novel oral, non-peptide glucagon like peptide-1 (GLP-1) receptor agonist, has demonstrated efficacy in improving body weight reduction and glycemic control. However, its potential benefits in improving cardiovascular (CV) risk factors have yet to be determined. We assessed the effect of orforglipron in participants with type 2 diabetes (T2D) and\/or overweight or obesity on blood pressure, lipid, and inflammatory biomarkers associated with risk for major adverse cardiovascular events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Using data from participants with available samples from Phase 2 trials of orforglipron in participants with T2D (N\u2009=\u2009361) or with overweight or obesity without diabetes mellitus (N\u2009=\u2009234), we performed an exploratory analysis of changes in CV risk markers. For the T2D study, participants mean age 59\u00a0years, 40% were assigned female at birth with a mean HbA<jats:sub>1c<\/jats:sub> of 8.1% and mean BMI of 35.3\u00a0kg\/m<jats:sup>2<\/jats:sup>; they received once daily orforglipron doses (3, 12, 24, 36, or 45\u00a0mg) or once weekly subcutaneous dulaglutide 1.5\u00a0mg, or placebo. In the obesity study, participants had a mean age 54\u00a0years, 60% were assigned female at birth, and mean BMI was 37.9\u00a0kg\/m<jats:sup>2<\/jats:sup>; they received once daily orforglipron (12, 24, 36, or 45\u00a0mg) or placebo. The change from baseline at 26\u00a0weeks (T2D study) or 36\u00a0weeks (obesity study) in blood pressure, lipids (cholesterol, triglycerides, Apolipoprotein B (ApoB), Apolipoprotein C3 (ApoC3), N-terminal pro-b-type natriuretic peptide (NT-pro-BNP), and inflammatory biomarkers (high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6)) were assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Significant placebo-adjusted decreases from baseline in blood pressure, low-density lipoprotein (LDL) cholesterol, triglycerides, ApoB, ApoC3, and hsCRP were observed following orforglipron treatment in participants with T2D and\/or overweight or obesity. In both studies, improvements in blood pressure, lipid parameters, and most of the evaluated biomarkers were of similar magnitude after treatment with 12\u00a0mg orforglipron as with 24, 36, and 45\u00a0mg.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Orforglipron treatment was associated with beneficial changes in CV risk markers in participants with T2D and in participants with overweight\/obesity without T2D. (Clinicaltrials.gov: NCT05048719, NCT05051579).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s12933-025-02781-x","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T09:01:02Z","timestamp":1749200462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes"],"prefix":"10.1186","volume":"24","author":[{"given":"Sean","family":"Wharton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manige","family":"Konige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Duffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiya","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Pirro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Kazda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieren","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"1","key":"2781_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","volume":"21","author":"CX Ma","year":"2022","unstructured":"Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022;21(1):74.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"2781_CR2","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/eurjpc\/zwae025","volume":"31","author":"A Welsh","year":"2024","unstructured":"Welsh A, Hammad M, Pina IL, Kulinski J. Obesity and cardiovascular health. Eur J Prev Cardiol. 2024;31(8):1026\u201335.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"2781_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20(1):189.","journal-title":"Cardiovasc Diabetol"},{"issue":"10193","key":"2781_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"4","key":"2781_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"24","key":"2781_CR6","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"19","key":"2781_CR7","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"9","key":"2781_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"1","key":"2781_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12933-022-01585-7","volume":"21","author":"O Mosenzon","year":"2022","unstructured":"Mosenzon O, Capehorn MS, De Remigis A, Rasmussen S, Weimers P, Rosenstock J. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Cardiovasc Diabetol. 2022;21(1):172.","journal-title":"Cardiovasc Diabetol"},{"key":"2781_CR10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2501006.","journal-title":"N Engl J Med"},{"issue":"9","key":"2781_CR11","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9\u2013119.","journal-title":"Circulation"},{"key":"2781_CR12","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice C. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S179-S218.","DOI":"10.2337\/dc24-S010"},{"issue":"24","key":"2781_CR13","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/j.jacc.2018.11.005","volume":"73","author":"DM Lloyd-Jones","year":"2019","unstructured":"Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC Jr, Sperling LS, Virani SS, Blumenthal RS. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American heart association and American college of cardiology. J Am Coll Cardiol. 2019;73(24):3153\u201367.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2781_CR14","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2337\/dc20-1843","volume":"44","author":"B Verges","year":"2021","unstructured":"Verges B, Duvillard L, Pais de Barros JP, Bouillet B, Baillot-Rudoni S, Rouland A, et al. Liraglutide increases the catabolism of apolipoprotein B100-containing lipoproteins in patients with type 2 diabetes and reduces proprotein convertase Subtilisin\/Kexin Type 9 expression. Diabetes Care. 2021;44(4):1027\u201337.","journal-title":"Diabetes Care"},{"issue":"6","key":"2781_CR15","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","volume":"3","author":"G Rakipovski","year":"2018","unstructured":"Rakipovski G, Rolin B, Nohr J, Klewe I, Frederiksen KS, Augustin R, et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-\/-) and LDLr(-\/-) Mice by a mechanism that includes inflammatory pathways. JACC Basic Transl Sci. 2018;3(6):844\u201357.","journal-title":"JACC Basic Transl Sci"},{"issue":"3","key":"2781_CR16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s12020-021-02945-1","volume":"75","author":"P Zhong","year":"2022","unstructured":"Zhong P, Zeng H, Huang M, Fu W, Chen Z. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. Endocrine. 2022;75(3):718\u201324.","journal-title":"Endocrine"},{"issue":"2","key":"2781_CR17","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/dom.14890","volume":"25","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Bhatta M, Davies M, Deanfield JE, Garvey WT, Khalid U, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023;25(2):468\u201378.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2781_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dbi19-0007","volume":"69","author":"A Chait","year":"2020","unstructured":"Chait A, Ginsberg HN, Vaisar T, Heinecke JW, Goldberg IJ, Bornfeldt KE. Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. Diabetes. 2020;69(4):508\u201316.","journal-title":"Diabetes"},{"issue":"8","key":"2781_CR19","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.clinthera.2022.06.010","volume":"44","author":"C Zhang","year":"2022","unstructured":"Zhang C, Ni J, Chen Z. Apolipoprotein B displays superior predictive value than other lipids for long-term prognosis in coronary atherosclerosis patients and particular subpopulations: a retrospective study. Clin Ther. 2022;44(8):1071\u201392.","journal-title":"Clin Ther"},{"key":"2781_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf067","author":"GG Schwartz","year":"2025","unstructured":"Schwartz GG, Szarek M, Esther Reijnders J, Jukema W, Bhatt DL, Bittner VA, et al. Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndrome. Eur J Prev Cardiol. 2025. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf067.","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"2781_CR21","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1253\/circj.CJ-24-0129","volume":"88","author":"CH Kim","year":"2024","unstructured":"Kim CH, Lee SH, Kim HK, Kim MC, Kim JH, Hong YJ, et al. Prognostic implications of N-Terminal Pro-B-Type natriuretic peptide in patients With Non-ST-elevation myocardial infarction. Circ J. 2024;88(8):1237\u201345.","journal-title":"Circ J"},{"issue":"3","key":"2781_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.hlc.2023.11.015","volume":"33","author":"CE Frary","year":"2024","unstructured":"Frary CE, Blicher MK, Olesen TB, Pareek M, Vishram-Nielsen JKK, Rasmussen S, Olsen MH. N-Terminal pro-brain type natriuretic peptide predicts cardiovascular events independently of arterial stiffness, assessed by carotid-to-femoral pulse wave velocity. Apparently Healthy Subjects Heart Lung Circ. 2024;33(3):392\u2013400.","journal-title":"Apparently Healthy Subjects Heart Lung Circ"},{"issue":"4","key":"2781_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/1354750X.2024.2335245","volume":"29","author":"RA Churchill","year":"2024","unstructured":"Churchill RA, Gochanour BR, Scott CG, Vasile VC, Rodeheffer RJ, Meeusen JW, Jaffe AS. Association of cardiac biomarkers with long-term cardiovascular events in a community cohort. Biomarkers. 2024;29(4):161\u201370.","journal-title":"Biomarkers"},{"issue":"38","key":"2781_CR24","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","volume":"39","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018;39(38):3499\u2013507.","journal-title":"Eur Heart J"},{"issue":"10","key":"2781_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. Daily Oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877\u201388.","journal-title":"N Engl J Med"},{"issue":"10400","key":"2781_CR26","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472\u201383.","journal-title":"Lancet"},{"issue":"10157","key":"2781_CR27","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"3","key":"2781_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/dom.13899","volume":"22","author":"I Avgerinos","year":"2020","unstructured":"Avgerinos I, Michailidis T, Liakos A, Karagiannis T, Matthews DR, Tsapas A, Bekiari E. Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2020;22(3):335\u201345.","journal-title":"Diabetes Obes Metab"},{"issue":"13","key":"2781_CR29","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"issue":"9","key":"2781_CR30","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.numecd.2024.04.015","volume":"34","author":"N Soroush","year":"2024","unstructured":"Soroush N, Nekouei Shahraki M, Mohammadi Jouabadi S, Amiri M, Aribas E, Stricker BH, Ahmadizar F. Statin therapy and cardiovascular protection in type 2 diabetes: The role of baseline LDL-Cholesterol levels. A systematic review and meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2024;34(9):2021\u201333.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"15","key":"2781_CR31","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1001\/jama.2018.2525","volume":"319","author":"EP Navarese","year":"2018","unstructured":"Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018;319(15):1566\u201379.","journal-title":"JAMA"},{"issue":"1","key":"2781_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/dom.13487","volume":"21","author":"N Matikainen","year":"2019","unstructured":"Matikainen N, Soderlund S, Bjornson E, Pietilainen K, Hakkarainen A, Lundbom N, et al. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study. Diabetes Obes Metab. 2019;21(1):84\u201394.","journal-title":"Diabetes Obes Metab"},{"key":"2781_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148559","author":"AR Tall","year":"2022","unstructured":"Tall AR, Thomas DG, Gonzalez-Cabodevilla AG, Goldberg IJ. Addressing dyslipidemic risk beyond LDL-cholesterol. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI148559.","journal-title":"J Clin Invest"},{"issue":"1","key":"2781_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"11","key":"2781_CR35","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/dom.12133","volume":"15","author":"K Hermansen","year":"2013","unstructured":"Hermansen K, Baekdal TA, During M, Pietraszek A, Mortensen LS, Jorgensen H, Flint A. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab. 2013;15(11):1040\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2781_CR36","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/dom.14373","volume":"23","author":"K Dahl","year":"2021","unstructured":"Dahl K, Brooks A, Almazedi F, Hoff ST, Boschini C, Baekdal TA. Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. Diabetes Obes Metab. 2021;23(7):1594\u2013603.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2781_CR37","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jdiacomp.2016.05.022","volume":"31","author":"M Mazidi","year":"2017","unstructured":"Mazidi M, Karimi E, Rezaie P, Ferns GA. Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Complications. 2017;31(7):1237\u201342.","journal-title":"J Diabetes Complications"},{"issue":"5","key":"2781_CR38","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.2337\/dc22-2397","volume":"46","author":"HC Gerstein","year":"2023","unstructured":"Gerstein HC, Lee SF, Pare G, Bethel MA, Colhoun HM, Hoover A, et al. Biomarker changes associated with both dulaglutide and cardiovascular events in the REWIND randomized controlled trial: a nested case-control post hoc analysis. Diabetes Care. 2023;46(5):1046\u201351.","journal-title":"Diabetes Care"},{"issue":"1","key":"2781_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","volume":"84","author":"MC Petrie","year":"2024","unstructured":"Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, et al. Semaglutide and NT-proBNP in obesity-related HFpEF: insights from the STEP-HFpEF program. J Am Coll Cardiol. 2024;84(1):27\u201340.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2781_CR40","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1111\/dom.14135","volume":"22","author":"R Nielsen","year":"2020","unstructured":"Nielsen R, Jorsal A, Tougaard RS, Rasmussen JJ, Schou M, Videbaek L, et al. The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes. Diabetes Obes Metab. 2020;22(11):2141\u201350.","journal-title":"Diabetes Obes Metab"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02781-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02781-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02781-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T09:01:06Z","timestamp":1749200466000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02781-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2781"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02781-x","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trials adhered to the principles of the Declaration of Helsinki and received approval from an independent ethics committee or institutional review board at each participating site. Participants provided informed consent for study participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}},{"value":"SW reports receiving grants from Novo Nordisk, speaking engagement fees from Bausch and Lomb, Eli Lilly and Company, Novo Nordisk, advisory board fees from Biohaven Pharmaceuticals, Inc., Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk; JR reports receiving grants from Applied Therapeutics, Boehringer Ingelheim, Eli Lilly and Company, Hanmi Pharmaceutical Co. Ltd, Intarcia, Novartis, Novo Nordisk, Oramed, Pfizer, Sanofi US Services Inc, travel support from applied therapeutics, Boehringer Ingelheim, Intarcia, Novo Nordisk, Oramed, Sanofi US Services Inc, serves on scientific advisory boards for applied therapeutics, Boehringer Ingelheim, Eli Lilly and Company, Intarcia, Novo Nordisk, Oramed, Sanofi US Services Inc, Zealand, speaker fees honoraria from Boehringer Ingelheim, Novo Nordisk, Sanofi US Services Inc, and consulting fees for Hanmi Pharmaceutical Co. MK was an employee at Eli Lilly, during which she contributed to this article. MK is currently employed at Pfizer Inc. which provided no review of, or other support for, this article. KM, YL, KD, JW, HB, VP, and CK are employees and shareholders of Eli Lilly and Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"240"}}